Facebook (NASDAQ:FB): BMO Capital expects analysts to raise their estimates for Facebook’s stock as investors further digest the company’s opportunities in social TV and second-screen behavior. The firm recommends buying the stock ahead of the company’s results and keeps an Outperform rating on the shares.
Lululemon (NASDAQ:LULU): Canaccord said Lululemon’s efforts to improve its processes across the supply chain are tracking ahead of schedule and resulting in improved product flow. The firm sees an upside to the company’s comps in the third and fourth quarter, as well a 2014. The firm reiterates its Buy rating, raising its price target on the stock to $90 from $85.
Cree (NASDAQ:CREE): After the company completed a teardown of the new Cree UR Series fluorescent replacement kit, Wedbush thinks the product has product margins well above conventional T8 and T5 fluorescent lamps, as well as profitability levels in-line with the company’s corporate average. The firm expects Cree’s margins from its chips and components businesses to rise and it keeps an Outperform rating on the shares, with a price target raised of $83, up from $78.
Forest Laboratories (NYSE:FRX): BofA/Merrill said Forest Labs’ conversion to once-daily Namenda XR is going well, and expects an almost complete conversion to XR before the generic launches. The firm reiterates its Buy rating and raised its price target to $53 from $49.